1. Scrip
  2. >>Therapy Areas

Beware The Ides of March? AnaptysBio's Imsidolimab Has Another Trial Failure

 
• By Alaric DeArment

After the 14 March announcement that the IL-36R agonist failed in an acne study, it appears to have better chances in generalized pustular psoriasis, an underserved orphan indication where the target is already validated.

AnaptysBio may have a better shot at a rarer skin condition with imsidolimab after acne trial failure • Source: Shutterstock

The market opportunity appears further narrowed for AnaptysBio, Inc.’s monoclonal antibody against the interleukin-36 receptor, imsidolimab, after it failed as a treatment for acne. Nevertheless, the drug still has a shot at tackling two orphan dermatological conditions that could enable it to command a higher price on the market.

AnaptysBio said after markets closed on 14 March that the Phase II ACORN clinical trial in moderate-to-severe acne did not...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

More from Therapy Areas

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.